Data / Drug companies / Posaconazole
Posaconazole: 29 companies and 36 products in the FDA NDC directory
Posaconazole is listed in the FDA National Drug Code Directory by 29 companies, with 36 products in commercial distribution. 30 of the products (83.3%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are tablet, delayed release; injection, solution; solution, and the newest product started marketing on February 24, 2025.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 29
- Products
- 36
- Generic (ANDA) products
- 30 (83.3%)
- Application numbers
- 21
- Routes
- Oral, Intravenous
- Brand names
- Noxafil
- openFDA record search
- api.fda.gov
Companies that list posaconazole
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Merck Sharp & Dohme LLC | 4 | suspension; tablet, coated | New drug applications (NDA) | June 8, 2021 |
| Bryant Ranch Prepack | 2 | tablet, delayed release | Generic drugs (ANDA) | September 15, 2023 |
| Camber Pharmaceuticals, Inc. | 2 | solution; tablet, delayed release | Generic drugs (ANDA) | December 23, 2024 |
| Glenmark Pharmaceuticals Inc., USA | 2 | injection, solution | Generic drugs (ANDA) | July 1, 2024 |
| Par Health USA, LLC | 2 | suspension; tablet, coated | Authorized generics (NDA) | March 29, 2023 |
| A2A Integrated Pharmaceuticals | 1 | tablet, delayed release | Generic drugs (ANDA) | May 16, 2024 |
| American Health Packaging | 1 | tablet, delayed release | Generic drugs (ANDA) | June 11, 2020 |
| Amneal Pharmaceuticals NY LLC | 1 | tablet, delayed release | Generic drugs (ANDA) | December 30, 2022 |
| Atlantic Biologicals Corp. | 1 | tablet, delayed release | Generic drugs (ANDA) | August 28, 2019 |
| Aurobindo Pharma Limited | 1 | tablet, delayed release | Generic drugs (ANDA) | July 18, 2024 |
| AvKARE | 1 | tablet, delayed release | Generic drugs (ANDA) | April 20, 2023 |
| AvPAK | 1 | tablet, delayed release | Generic drugs (ANDA) | May 9, 2022 |
| Biocon Pharma Inc. | 1 | tablet, delayed release | Generic drugs (ANDA) | March 8, 2022 |
| Bryant Ranch Prepack | 1 | tablet, delayed release | Generic drugs (ANDA) | September 15, 2023 |
| Dr. Reddy's Laboratories Inc. | 1 | tablet, delayed release | Generic drugs (ANDA) | April 7, 2022 |
| Eugia US LLC | 1 | injection | Generic drugs (ANDA) | December 26, 2023 |
| Fresenius Kabi USA, LLC | 1 | injection, solution | Generic drugs (ANDA) | December 26, 2023 |
| Gland Pharma Limited | 1 | injection, solution | Generic drugs (ANDA) | December 26, 2023 |
| Golden State Medical Supply, Inc. | 1 | tablet, delayed release | Generic drugs (ANDA) | May 10, 2022 |
| Hikma Pharmaceuticals USA Inc. | 1 | suspension | Generic drugs (ANDA) | March 29, 2023 |
| I3 Pharmaceuticals, LLC | 1 | tablet, delayed release | Generic drugs (ANDA) | September 15, 2023 |
| Lannett Company, Inc. | 1 | tablet, delayed release | Generic drugs (ANDA) | August 28, 2019 |
| Lupin Pharmaceuticals, Inc. | 1 | tablet, delayed release | Generic drugs (ANDA) | February 17, 2021 |
| Major Pharmaceuticals | 1 | tablet, delayed release | Generic drugs (ANDA) | February 3, 2021 |
| Mylan Institutional LLC | 1 | solution | Generic drugs (ANDA) | March 22, 2024 |
| NorthStar Rx LLC | 1 | tablet, delayed release | Generic drugs (ANDA) | April 2, 2023 |
| Novadoz Pharmaceuticals LLC | 1 | tablet, coated | Generic drugs (ANDA) | February 24, 2025 |
| Par Health USA, LLC | 1 | injection | Generic drugs (ANDA) | January 1, 2023 |
| SpecGx LLC | 1 | tablet, delayed release | Generic drugs (ANDA) | May 10, 2022 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet, delayed release | 20 | 55.6% |
| Injection, solution | 4 | 11.1% |
| Solution | 3 | 8.3% |
| Suspension | 3 | 8.3% |
| Tablet, coated | 3 | 8.3% |
| Injection | 2 | 5.6% |
| Powder, for suspension | 1 | 2.8% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 30 | 83.3% |
| New drug applications (NDA) | 4 | 11.1% |
| Authorized generics (NDA) | 2 | 5.6% |
Pharmacologic classes
| Class | Products |
|---|---|
| Azole Antifungal | 36 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.